Evaluating Tumor Response of Non-Small Cell Lung Cancer Patients With 18F-Fludeoxyglucose Positron Emission Tomography: Potential for Treatment Individualization
Creators
- 1. Medical Radiation Physics, Stockholm University and Karolinska Institutet, Stockholm (Sweden)
- 2. RaySearch Laboratories AB, Stockholm (Sweden)
- 3. Medical Radiation Physics, Karolinska Institutet, Stockholm (Sweden)
- 4. Department of Radiation Oncology, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht (Netherlands)
- 5. Department of Radiation Physics and Department of Medical and Health Sciences, Linköping University, Linköping (Sweden)
Description
Objective: To assess early tumor responsiveness and the corresponding effective radiosensitivity for individual patients with non-small cell lung cancer (NSCLC) based on 2 successive 18F-fludeoxyglucose positron emission tomography (FDG-PET) scans. Methods and Materials: Twenty-six NSCLC patients treated in Maastricht were included in the study. Fifteen patients underwent sequential chemoradiation therapy, and 11 patients received concomitant chemoradiation therapy. All patients were imaged with FDG before the start and during the second week of radiation therapy. The sequential images were analyzed in relation to the dose delivered until the second image. An operational quantity, effective radiosensitivity, αeff, was determined at the voxel level. Correlations were sought between the average αeff or the fraction of negative αeff values and the overall survival at 2 years. Separate analyses were performed for the primary gross target volume (GTV), the lymph node GTV, and the clinical target volumes (CTVs). Results: Patients receiving sequential treatment could be divided into responders and nonresponders, using a threshold for the average αeff of 0.003 Gy−1 in the primary GTV, with a sensitivity of 75% and a specificity of 100% (P<.0001). Choosing the fraction of negative αeff as a criterion, the threshold 0.3 also had a sensitivity of 75% and a specificity of 100% (P<.0001). Good prognostic potential was maintained for patients receiving concurrent chemotherapy. For lymph node GTV, the correlation had low statistical significance. A cross-validation analysis confirmed the potential of the method. Conclusions: Evaluation of the early response in NSCLC patients showed that it is feasible to determine a threshold value for effective radiosensitivity corresponding to good response. It also showed that a threshold value for the fraction of negative αeff could also be correlated with poor response. The proposed method, therefore, has potential to identify candidates for more aggressive strategies to increase the rate of local control and also avoid exposing to unnecessary aggressive therapies the majority of patients responding to standard treatment
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2014.10.012Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2014.10.012;
- PII
- S0360-3016(14)04263-1;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 91
- Journal Issue
- 2
- Journal Page Range
- p. 376-384
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 47028181
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- CHEMOTHERAPY; CORRELATIONS; DATA; FLUORINE 18; IMAGES; LUNGS; LYMPH NODES; NEOPLASMS; PATIENTS; POSITRON COMPUTED TOMOGRAPHY; RADIATION DOSES; RADIOSENSITIVITY; RADIOTHERAPY; SPECIFICITY; VALIDATION
- Descriptors DEC
- BETA DECAY RADIOISOTOPES; BETA-PLUS DECAY RADIOISOTOPES; BODY; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; DISEASES; DOSES; EMISSION COMPUTED TOMOGRAPHY; FLUORINE ISOTOPES; HOURS LIVING RADIOISOTOPES; INFORMATION; ISOMERIC TRANSITION ISOTOPES; ISOTOPES; LIGHT NUCLEI; LYMPHATIC SYSTEM; MEDICINE; NANOSECONDS LIVING RADIOISOTOPES; NUCLEAR MEDICINE; NUCLEI; ODD-ODD NUCLEI; ORGANS; RADIOISOTOPES; RADIOLOGY; RESPIRATORY SYSTEM; SENSITIVITY; TESTING; THERAPY; TOMOGRAPHY
Optional Information
- Copyright
- Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.